Is Omnipod® Right For Me?
A bit about insulin pump therapy
An insulin pump is a device that delivers insulin in place of multiple daily injections.
A continuous amount of rapid acting insulin is delivered 24 hours a day through a cannula placed under the skin. This is known as basal insulin, but it’s sometimes called background insulin.
With automated insulin delivery systems, these basal doses are automatically calculated based on glucose levels and delivered every five minutes - which can mean less diabetes ‘work’ for you.
Additional insulin is delivered for meals and blood glucose corrections - these are known as bolus doses.
There is more than one type of insulin pump.
Tethered pumps
Tubeless pumps
Why Omnipod?
Omnipod was created out of a father’s mission to free his son from the burden of multiple daily injections. Our mission to simplify life for those living with type 1 diabetes remains.
From parents frustrated by the need to deliver frequent injections, to adults who’ve written off insulin pumps altogether, Omnipod can simplify life with up to three days (up to 72 hours) of continuous, tubeless insulin delivery, with no need for multiple daily injections.
- Discreet: The Pod is small enough to be worn under clothing. Placed directly on the body with adhesive, there’s no tubing to worry about.
- Convenient: Deliver bolus insulin with just a few fingertaps using the wireless Controller (Omnipod® 5) or Personal Diabetes Manager (Omnipod DASH®).
- Simplified: The built-in Bolus Calculator reduces mealtime math.
- Waterproof‡: The Pod can be worn in the shower, swimming pool or sea.
We have two systems: the Omnipod DASH® System and our next generation automated insulin delivery (AID) system, Omnipod® 5.
Omnipod 5 is the first and only tubeless automated insulin delivery system that works with the leading sensor brands*.
Compatible with your choice of the Dexcom G7 sensor or FreeStyle Libre 2 Plus sensor, you can get started with all the benefits of automated insulin delivery without the hassle of having to switch your continuous glucose monitor.
Pod Therapy is insulin pump therapy, but not as you know it!
* Automated Mode requires Dexcom G7 or FreeStyle Libre 2 Plus sensor. Boluses for meals and corrections are still needed. Sensor requires a separate prescription and is sold separately.
Meet our tubeless, wearable Omnipod lineup
Omnipod 5 Automated Insulin Delivery System
Now compatible with the Dexcom G7 sensor and FreeStyle Libre 2 Plus sensor!* Omnipod 5 automatically adjusts insulin every five minutes, helping you to stay in range throughout the day and night1,2.
Omnipod DASH® Insulin Management System
You’re in control with the Omnipod DASH Personal Diabetes Manager. Discover discreet, precise insulin dosing and customisable programmes designed to fit around your lifestyle.
A 37-year road to freedom
Clare was diagnosed with type 1 diabetes over 40 years ago. After decades of mutiple daily injections, blood glucose swings, and dangerous lows, Omnipod helped her simplify life with diabetes.
I don’t have to spend as much time thinking about diabetes.
Clare F.
Podder® since 2013
Ready to find out more?
Speak to your healthcare provider to find out more!
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL or >10 mmol/L in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Mean time <70 mg/dL or < 3.9 mmol/L in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
2. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL or >10 mmol/L in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL or < 3.9 mmol/L in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-mo Omnipod 5 = 2.46%, P=0.0204. Results measured by CGM. Study funded by Insulet.